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Abstract
Background The aim of this study was to evaluate the
need of axillary staging in breast cancer patients showing
exclusive lymphatic drainage to the internal mammary
chain (IMC).
Methods A total of 2203 patients treated for breast car-
cinoma in three participating hospitals between July 2001
and July 2008 were analyzed. Only patients showing
drainage to the IMC on preoperative lymphoscintigraphy
were included. The number of harvested IMC sentinel
lymph nodes (SLNs), axillary SLNs, and metastases were
recorded. Finally, the follow-up of this group of patients
was analyzed.
Results In 25/426 patients, drainage was exclusively to
the IMC. Exploration of the axilla resulted in the harvest-
ing of blue SLNs in 9 patients (36%) and the retrieval of an
enlarged lymph node in 1 patient. In 4 of the remaining 15
patients, an axillary lymph node dissection (ALND) was
done. Lymph node metastases were found in 3 patients who
had blue axillary SLNs and in 1 patient who underwent
ALND. In the 11 patients who had no blue SLNs and no
ALND, no axillary recurrences were observed during fol-
low-up (median = 26 months).
Conclusions Proper staging of the axilla remains crucial
in patients showing exclusive drainage to the IMC. When
no axillary node can be retrieved, ALND remains subject
to discussion.
Introduction
The introduction of the sentinel lymph node (SLN) biopsy
has renewed the interest in regional lymph nodes outside
the axilla as a potential site of regional lymph node
metastases. SLNs in the internal mammary chain (IMC) are
observed on preoperative lymphoscintigraphy in up to 30%
of patients [1–3]. Although harvesting these IMC-SLNs is
discussed by some authors, retrieval of them is advocated
by others [4, 5], not only as proof of principle but also
because nonsurgical treatment may be inﬂuenced by the
presence or absence of metastases in these nodes, espe-
cially when no axillary SLNs are found [6, 7].
In most patients IMC-SLNs are visualized together with
axillary SLNs, while in 2.6–4% of these patients isolated
lymphatic drainage to the IMC is seen, with no transport to
axillary lymph nodes [7, 8]. While axillary lymph node
dissection (ALND) is commonly advised for patients when
there are no axillary SLNs on preoperative lymphoscin-
tigraphy, there is no agreement on what to do when there is
lymphatic drainage to the IMC without drainage to the
axilla [9]. The question is whether solitary IMC-SLNs are
sufﬁcient for staging, or if axillary dissection, SLN biopsy
following patent blue injection, or a wait-and-see policy is
required for adequate staging.
In the present study we analyzed the case histories of
patients who showed isolated lymphatic drainage to
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raphy. The aim of the present study was to address whether
axillary staging should be done in these patients.
Materials and methods
In this retrospective study, a cohort of 2203 consecutive
patients diagnosed with cT1-2N0 breast cancer in three
hospitals in the Middle Netherlands between July 2001 and
July 2008 underwent surgery that included SLN biopsy as a
staging procedure. Lymphoscintigraphy protocols were
different at the three hospitals (Fig. 1). In hospitals A and
B, patients received a combination of peritumoral, intra-
tumoral, and subcutaneous injection of
99mTc nanocolloı ¨d
with an average dose of 70 MBq in a total volume of 0.6 cc
of physiologic saline. In case of a nonpalpable breast
tumor, the injection of the radiopharmacon was guided by
ultrasound or stereotaxia. Surgery was done on the same
day. In hospital C, patients were injected with
99mTc
nanocolloı ¨d (80–550 MBq) in 0.5 cc of physiologic saline
intra- and peritumorally guided by ultrasound or stereo-
taxia using a 1- or a 2-day protocol [10]. In all hospitals the
nuclear physician used both static images and a gamma-ray
detection probe (Europrobe, PI Medical Diagnostics) to
detect and mark the SLN. At the start of the operation,
1-2 cc of patent blue (Bleu patente0 V ‘Guerbet’) was
injected peritumorally in all patients. In addition, in
hospital A and B, 1 cc of patent blue was injected
subcutaneously.
Sentinel lymph node retrieval
When preoperative lymphoscintigraphy showed axillary
SLNs, they were retrieved using a gamma-ray detection
probe intraoperatively. A parasternal intercostal explora-
tion was done to retrieve apparent SLNs in the IMC [2]. If
no axillary SLN was visualized on preoperative lympho-
scintigraphy, the axilla was still explored using the gamma-
ray detection probe and patent blue irrespective of the
presence of internal mammary SLNs. Axillary exploration
and subsequent retrieval of a blue and/or hot SLN was
considered a reliable staging procedure. In case no blue
node was retrieved from the axilla, surgical strategies were
different in the three hospitals: in hospital C these patients
underwent ALND and in hospitals A and B a wait-and-see
policy was common.
All SLNs were formalin ﬁxed and 5-lm-thick step
sections were cut at 250-lm intervals for staining with
hematoxylin and eosin (H&E) and immunohistochemical
cytokeratin-8. The size of the metastases found in the
lymph nodes were deﬁned as follows: macrometastases
were metastases of 2.0 mm or larger, micrometastases
were larger than 0.2 mm and smaller than 2.0 mm, and
isolated tumor cells were smaller than 0.2 mm in diameter
[11].
The proportion of patients with isolated lymphatic
drainage to the IMC was assessed. In the selection of
patients with isolated lymphatic drainage to the IMC, the
yield of the patent-blue-guided axillary exploration was
evaluated by describing the proportion of patients with blue
sentinel nodes, the frequency of lymph node metastases
when ALND was done, and the occurrence of axillary
relapses when no ALND was done.
Results
Lymphatic drainage to the IMC was observed in 426/2203
patients (19%), while exclusive IMC drainage was seen in
25/2203 (1.1%) patients (Fig. 2). Baseline characteristics
of the 25 patients with exclusive drainage to the IMC are
given in Table 1. In 16/25 (64%) patients the tumor was
located in the upper inner quadrant.
In the 25 patients with exclusive lymphoscintigraphic
visualization of SLN drainage to the IMC, the lymph nodes
could be extirpated successfully in 16 patients (64%). In 12
of these 16 patients the node was hot and in 4 patients the
node was hot and blue. Metastases were detected in the
IMC-SLNs in 4 of the 16 patients (Fig. 3): isolated tumor
cells in 2 patients, micrometastasis in 1 patient, and ma-
crometastasis in 1 patient.
In addition to the exploration of the IMC, the axilla was
explored for hot and/or patent-blue-containing SLNs.
Hospital A  Hospital B  Hospital C 
Peritumoural, intratumoural and 
subcutaneous injection 70MBq 
99m Tc 
Intra-
/peritumoural 
injection of 
80-550 
99mTC 
Injection 1-2 cc patent blue 
Wait and 
see 
Wait and 
see 
ALND 
No axillary node 
Fig. 1 Sentinel node protocol for each participating hospital
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123Additional nodes were retrieved from the axilla in 14/25
patients. Ten patients underwent a successful SLN retrieval
from the axilla: in nine patients a blue lymph node was
retrieved from the axilla and in another patient an enlarged
node was removed. The remaining four patients underwent
ALND. Four of the 14 patients who underwent axillary
staging had axillary lymph node metastases: in three
patients who had SLN staging of the axilla and in 1 patient
who had ALND following a failed exploration for a blue
SLN. Axillary lymph node involvement was categorized as
macrometastasis (n = 1), micrometastasis (n = 2), and
isolated tumor cells (n = 1) (Table 2). Additional axillary
staging by SLN biopsy or ALND in patients with exclusive
drainage to the IMC on preoperative lymphoscintigraphy
resulted in an increase in frequency of regional lymph node
metastases from 16 to 28% (4/25 vs. 7/25 patients). One
patient had axillary metastases concomitant with IMC
metastases. Two patients with axillary metastases had their
postsurgical treatment adjusted to adjuvant chemothera-
peutic treatment and one patient chose not to receive
additional chemotherapy (Table 2).
The overall median follow-up was 26 months (range =
4–82). A total of 3/25 (12%) patients died after a median of
53 months (range = 21–72). One of these patients had
undergone removal of an axillary node containing isolated
tumor cells (ITC). This patient received locoregional
radiotherapy on the IMC and no axillary dissectionhad been
performed. In another patient only an IMC-SLN without
tumor cells was harvested and no axillary nodes were
removed. These two patients died due to progression of the
breast carcinoma; one suffered bone metastases and the
other suffered skinrecurrence and distantmetastases toliver
and lungs. The third patient showed micrometastases in the
IMC; no axillary dissectionwas performed and locoregional
radiotherapy was given on the IMC. This patient was diag-
nosed with simultaneous esophageal carcinoma and died
due to progression of this carcinoma. In none of these
patients was axillary recurrence observed.
Discussion
Although the utility of harvesting internal mammary chain
SLNs is discussed by some authors, we strongly believe
that there is a rationale for retrieving these nodes. Tumor
staging will be more accurate after histological judgment of
all sentinel lymph nodes, especially in the absence of
axillary SLNs that might inﬂuence adjuvant treatment [2, 6,
7]. However, we realize that this debate will continue as
long as there are no reliable results of randomized trials
regarding the treatment principle of intramammary chain
metastases.
In this large retrospective cohort of patients who
underwent SLN biopsy as part of breast cancer surgery, 1%
had exclusive lymphoscintigraphic drainage to the IMC.
Axillary staging revealed metastases in a clinically relevant
additional proportion of patients. We realize that the ret-
rospective design of the study has its drawbacks. Despite
this, it is this one of the largest studies of this important
clinical dilemma [6, 7].
The type of nuclear protocol is important to the number
of nodes found in the IMC. After intra- or peritumoral
Fig. 2 Preoperative imaging of IMC-SLNs
Table 1 Baseline characteristics
Baseline characteristics
Median age (years) 60 (48–78)
Tumor quadrant
Upper outer 6 (24%)
Upper inner 16 (64%)
Lower inner 2 (8%)
Central 1 (4%)
Tumor histology
Ductal 19 (76%)
Lobular 3 (12%)
Ductolobular 2 (8%)
Papillary 1 (4%)
Median tumor size (mm) 15 (5–80)
Estrogen receptor expression 21 (84%)
Progesterone receptor expression 17 (68%)
Her2Neu overexpression 5 (20%)
B&R
1 9 (36%)
2 8 (32%)
3 7 (28%)
Unknown 1 (4%)
MAI 5 (0-45)
MAI mitose activity index, B&R Bloom and Richardson grade
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123injection of the radiopharmacon, the number of nodes
found in the IMC is higher than after subcutaneous injec-
tion. This can be explained by the differences in drainage
patterns of the breast. Tumors deeper in the breast more
often tend to drain to the IMC than do superﬁcial tumors.
The deep and the superﬁcial drainage systems in the breast
are not connected, so when injecting only subcutaneously,
the deep drainage system is missed and the SLNs con-
nected to the deep drainage system are missed as well [12].
In this study all patients had an intra- or a peritumoral
injection, and in hospitals A and B in combination with a
subcutaneous injection. All patients underwent axillary
exploration, although in a SLN could not be harvested in
all cases. Furthermore, it is known that tumors in the upper
inner quadrant of the breast tend to drain more often to the
IMC [10, 13], and indeed most patients in this study had
tumors located in the upper inner quadrant of the breast.
Despite the absence of lymphoscintigraphic axillary
drainage, axillary staging detected lymph node metastases
with similar frequency as SLN biopsy revealed in the IMC
node. The observed absence of lymphoscintigraphic
drainage to the axilla could not be attributed to blockage of
this path by massive axillary lymph node involvement, as
suggested by others [7]. Instead, the extent of metastatic
lymph node involvement was comparable and limited in
both the axilla and the IMC, as described by others [14,
15]. Furthermore, the presence of lymph node metastases
in the axilla and the IMC was not interdependent. Hence,
additional axillary staging led to an increased overall fre-
quency of regional lymph node metastases.
As described earlier, younger age could inﬂuence the
detection of SN in the IMC [2]; however, in this study we
could not conﬁrm this. Tumor stage (I-II) is also described
as being a factor in identifying IMC-SLNs and tumor
positivity in these nodes. Indeed, the majority of the
patients described in this study had stage I-II breast cancer.
One patient had an 8-cm tumor and another patient had a
7-cm tumor on histopathology. According to the Dutch
guidelines for breast carcinoma [16], patients with tumors
clinically smaller than 5 cm (T2 tumors) undergo SN
Total number of patients
N=2208 
IMC only on Lymphoscintigraphy: 
N=25, , 16 nodes removed 4 
metastases found
Patent blue and gamma ray
detection probe axillary 
exploration  
N=25  
No axillary node, 
additional ALND 
N=4 
1/4, metastases 
0/4 axillary recurrence
On palpation
N=1 
0 metastases 
0 axillary 
recurrence 
No axillary node, 
follow up  
N=11 
0/11 axillary recurrence 
Axillary  node 
removed 
N=9 
3/9 metastases 
0/9 axillary recurrence 
Fig. 3 Flowchart
Table 2 Sentinel node and
tumor characteristics
Patient Age
(years)
Tumor
size (mm)
Location of
metastasis
Grade of
metastasis
Recurrence Additional
treatment
1 60 70 Axillary Micro No Chemotherapy
2 59 9 Axillary ITC Yes No
3 57 10 Axillary Micro No No
4 73 19 IMC Micro No No
5 62 16 IMC ITC No No
6 60 25 IMC ITC No No
7 58 16 Axillary and IMC Macro No Chemotherapy
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123biopsy and tumors larger than 5 cm undergo primary
ALND. Both these patients had a secondary ALND which
showed no additional metastases.
In this study, the IMC-SLN could not be harvested in
nine patients. Others described a conservative approach to
harvesting IMC-SLNs as a limited number of patients
would beneﬁt from it and the possible morbidity of har-
vesting IMC-SLNs should weigh against the beneﬁt. We
demonstrated that harvesting the IMC-SLN did not change
the adjuvant treatment in most cases, so indeed a critical
approach to selection of patients in whom the IMC-SLN
can be harvested is justiﬁed [5.]
The retrieval from the axilla of blue SLNs that contain
metastases demonstrates the complementary aspect of pat-
ent blue and radioactive tracer injection when performing
SLN biopsy in breast cancer patients. In that respect, our
ﬁndings are in line with the observation of others [6, 7, 17].
Van der Ploeg et al. [7] performed patent-blue-guided
axillary exploration in a group of 82 patients with exclusive
lymphoscintigraphic drainage to the IMC and blue SLNs
were identiﬁed in 62 of these patients. We conﬁrm the need
for additional axillary staging in patients with exclusive
lymphoscintigraphic drainage to the IMC [18].
Optimal staging of breast cancer patients becomes ever
more important. Even ITCs and micrometastases in
regional lymph nodes may have a prognostic effect, and the
indications for adjuvant chemotherapy will be expanded to
patients with them [19]. In the present study, in those
patients with no axillary drainage on lymphoscintigraphy,
three patients were proposed to receive adjuvant chemo-
therapy because of additional metastases in the axilla.
Whether to perform an axillary dissection when explo-
ration for a blue SLN is unsuccessful is more difﬁcult to
answer. Some authors argue that in the case of successful
retrieval of IMC-SLNs, axillary exploration for blue SLNs
is a sufﬁcient means of staging. In their view, when
exploration of the axilla does not reveal a blue SLN, there
is no lymphatic drainage to the axilla and an ALND may be
omitted safely [7]. In line with their results, we observed no
axillary recurrences in the patients in the wait-and-see
group. However, our data can be used to support the ALND
policy, too, since axillary lymph node metastases were
found in one patient in whom an ALND was performed
when no axillary SN could be identiﬁed. Furthermore, the
survival and recurrence rates of the patients in this study
are comparable to those in the literature [3, 7, 15].
In order to reach consensus on whether an additional
ALND is needed when no other than IMC-SLN’s are
found, more data are needed. Because a prospective ran-
domized trial on this subject probably will not be feasible,
we encourage other authors to present their data likewise.
In conclusion, when preoperative lymphoscintigraphy
shows exclusive lymphatic drainage to the internal
mammary chain, proper staging should include exploration
of the axilla for blue SLNs. Metastases can be found in a
relevant additional proportion of patients and postsurgical
treatment could be adjusted accordingly. Performing an
ALND when no axillary node can be retrieved remains
subject to debate.
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